Trudy G Oliver

Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text Cite

Basal Cell of Origin Resolves Neuroendocrine-Tuft Lineage Plasticity in Cancer

Conference JOURNAL OF THORACIC ONCOLOGY · August 2025 Link to item Cite

Cataloging genomic and transcriptomic features of relapsed SCLC.

Conference Journal of Clinical Oncology · June 2025 8107Background: Relapsed small cell lung cancer (R-SCLC) is characterized by poor outcomes and treatment resistance. The mech ... Full text Cite

The Nrf2^E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53^{floxed/floxed}/Cdkn2a^{floxed/floxed} mice

Conference CANCER RESEARCH · June 15, 2022 Link to item Cite

Trudy G Oliver

Scholarly Works - Conferences

Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.

Basal Cell of Origin Resolves Neuroendocrine-Tuft Lineage Plasticity in Cancer

Cataloging genomic and transcriptomic features of relapsed SCLC.

The Nrf2E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53floxed/floxed/Cdkn2afloxed/floxed mice

The Nrf2^E79Q activating mutation accelerates growth of pure-small cell lung cancer but not combined small cell lung cancer Tp53^{floxed/floxed}/Cdkn2a^{floxed/floxed} mice